The Centre for Outcomes Research and Economic Evaluation for Health (C2H) is an esteemed department of the National Institute of Public Health in Japan, established in 2018. The organisation conducts rigorous academic research on cost-effectiveness evaluations and plays a crucial role in the official evaluation process. In a nation where public healthcare expenditure is continually increasing, C2H’s work is invaluable. They strive to balance the cost and outcome of healthcare technologies, providing crucial data and materials for evidence-based health policy. The ultimate goal is to enhance the sustainability of the public healthcare system. C2H is a beacon of knowledge for experts conducting cost-effectiveness evaluations, offering guidelines and analytical tools. Furthermore, they also guide manufacturers in conducting scientifically sound analyses and help citizens and healthcare professionals understand the value and implications of their evaluations. Below are some insights to Valbenazine market access.
In May 2023, Valbenazine was reimbursed and its drug price was set at JPY 2331.2 for a Dysval® capsule 40mg in Japan, determined via the Similar Efficacy Comparison Method with a 5% premium. This pricing strategy is an example of dynamic pricing, a common practice in pharmaceutical pricing strategy. The drug was designated for the Cost-effectiveness Evaluation with an H2 classification, reflecting its significant value story.
The target population for Valbenazine is patients with tardive dyskinesia whose symptoms have not improved sufficiently by reducing or discontinuing drugs for underlying diseases. Given the limited treatment options for this group, the comparator for the cost-effectiveness evaluation was “watchful waiting”.
The manufacturer conducted a systematic review of randomised controlled trials to evaluate the drug’s additional benefits. This review included a mixed-model meta-analysis that compared Valbenazine with a placebo. The results showed that Valbenazine significantly improved patients’ symptoms. This reaffirms the value-based healthcare benefits of the drug.
The manufacturer conducted a cost-utility analysis using a microsimulation model. This model accounted for responses from interventions, prescription of antipsychotic drugs, and recurrence of underlying diseases. Interestingly, the results of this analysis further substantiated the benefits of Valbenazine, demonstrating its cost-effectiveness and aligning with the principles of value-based healthcare 2024.
💡 *What does the future hold for healthcare in the MENA region?*
The rise of generics and biologics is set to transform healthcare in the Middle East and North Africa, driven by government reforms and an evolving regulatory landscape. Learn how these advancements are making life-saving therapies more accessible and cost-effective for patients across the region.
#SyenzaNews #HealthcareInnovation #pharmaceuticals #MarketAccess
🚨 *What does Trump’s latest healthcare policy shift mean for the future of U.S. health initiatives?*
In a bold move, President Trump has reversed key Biden-era healthcare directives, altering approaches to COVID-19, drug pricing, and international health partnerships. This could reshape our healthcare landscape significantly. Dive into the article to understand how these changes could impact patients, providers, and the industry at large!
#SyenzaNews #healthcare #healthcarepolicy #innovation
🚨 *What does the U.S. withdrawing from the WHO mean for global health?*
President Trump’s executive order to begin the withdrawal process raises serious concerns about the future of global health security. From financial disparities to a shift in international partnerships, the implications could reshape our collective ability to combat pandemics and health crises.
Dive into our article to understand the potential impacts on health outcomes and the quest for new alliances.
#SyenzaNews #globalhealth #healthcarepolicy
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
